Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Arq. neuropsiquiatr ; 77(12): 881-887, Dec. 2019. tab, graf
Article in English | LILACS | ID: biblio-1055207

ABSTRACT

ABSTRACT Induction of long-term potentiation (LTP) increases the storage capacity of synapses in the hippocampal dentate gyrus (DG). Irisin is a myokine generated from FNDC5 (a gene precursor) during exercise. Although intra-cornu ammonis 1 administration of irisin fortifies LTP in mice with Alzheimer's disease, the effects of intra-DG injection of irisin on the LTP in rats remains to be elucidated in vivo. In this study, male Wistar rats were randomly divided into a control group (saline), irisin (0.5, 1, and 1.5 μg/rat), and dimethyl sulfoxide (DMSO). After treatment, the population spike (PS) amplitude and slope of excitatory postsynaptic potentials (EPSP) were measured in the DG of rats in vivo. Moreover, following completion of the experiments, the stimulating and recording sites in the hippocampus were confirmed histologically from brain sections. Furthermore, biochemical assays like malondialdehyde (MDA), total antioxidant capacity (TAC), and total oxidant status (TOS) were evaluated (the antioxidant markers were analyzed in the plasma). Our results suggest that all doses of irisin (0.5, 1, 1.5 μg/rat) caused an increase in the EPSP slope and PS amplitude when compared with the control group. In addition, the results obtained showed that irisin decreased TOS and MDA levels while increasing TAC levels as a marker of lipid peroxidation in plasma. The present report provides direct evidence that irisin affects the activity-dependent synaptic plasticity in the dentate gyrus.


RESUMO A indução de potenciação de longo prazo (LTP) aumenta a capacidade de armazenamento das sinapses no giro denteado (DG) do hipocampo. A irisina é uma miocina gerada a partir do FNDC5 (um precursor genético) durante o exercício. Embora a administração intra-Cornu Ammonis1 de irisina fortaleça a LTP em camundongos com doença de Alzheimer, os efeitos da injeção intra-denteada de irisina sobre a LTP em ratos ainda precisam ser elucidados in vivo. Neste estudo, ratos Wistar machos foram divididos aleatoriamente em um grupo controle (solução salina), irisina (0,5, 1 e 1,5 μg / rato) e dimetilsulfóxido (DMSO). Após o tratamento, a amplitude do pico populacional (PS) e a variação dos potenciais pós-sinápticos excitatórios (EPSP) foram medidos no DG de ratos in vivo. Além disso, após a conclusão das experiências, os locais de estimulação e registro no hipocampo foram confirmados histologicamente a partir de secções do cérebro. Adicionalmente, ensaios bioquímicos como malondialdeído (MDA), capacidade antioxidante total (TAC) e status oxidante total (TOS) foram avaliados (os marcadores antioxidantes foram analisados no plasma). Nossos resultados sugerem que todas as doses de irisina (0,5, 1, 1,5 μg / rato) causaram um aumento na variação da EPSP e na amplitude da PS quando comparadas com o grupo controle. Além disso, os resultados obtidos mostraram que a irisina diminuiu os níveis de TOS e MDA, enquanto aumentou os níveis de TAC como um marcador da peroxidação lipídica no plasma. O presente estudo fornece evidências diretas de que a irisina afeta a plasticidade sináptica dependente de atividade no DG.


Subject(s)
Animals , Male , Neuropeptides/administration & dosage , Fibronectins/administration & dosage , Long-Term Potentiation/drug effects , Dentate Gyrus/drug effects , Microinjections/methods , Reference Values , Time Factors , Lipid Peroxidation , Random Allocation , Reproducibility of Results , Rats, Wistar , Brain-Derived Neurotrophic Factor/analysis , Brain-Derived Neurotrophic Factor/drug effects , Excitatory Postsynaptic Potentials/drug effects , Malondialdehyde/blood , Antioxidants/analysis
2.
Rev. bras. oftalmol ; 55(9): 669-72, set. 1996. ilus
Article in Portuguese | LILACS | ID: lil-192660

ABSTRACT

Apresenta-se o resultado preliminar da hipotonia persisitente pós-trabeculectomia, com danos cório-retinianos, feito com a injeçäo intra-vesicular de sangue atólogo. O procedimento é de simples execuçäo, baixa morbidade, e capaz de melhorar o estado anátomo-funcional de 75 por cento dos olhos, podendo ser repetido se uma primeira tentativa fracassa


Subject(s)
Humans , Fibrinogen/administration & dosage , Fibronectins/administration & dosage , Ocular Hypotension/therapy , Plasminogen/administration & dosage , Trabeculectomy/adverse effects
3.
Korean Journal of Ophthalmology ; : 5-11, 1990.
Article in English | WPRIM | ID: wpr-22322

ABSTRACT

Topical fibronectin, autologous and homologous, was used to treat nine patients (eleven eyes) with persistent corneal epithelial defects and corneal ulcers that failed to improve with standard therapy. The fibronectin was purified from autologous and homologous plasma by gelatin-Sepharose 4B affinity chromatography and administered topically, 500 micrograms/ml five times a day, for three weeks. Complete or nearly complete reepithelialization was achieved in all patients regardless of the source of fibronectin, autologous or homologous. But healing times varied. The average healing time was 41.7 +/- 14.7 days (35.7 +/- 12.4 days for autologous, 50.8 +/-14.4 days for homologous). Ocular symptoms were relieved significantly, and no side effects were observed. Over an average follow-up period of 5.2 months, no recurrences were noted. The results showed that homologous, as well as autologous, fibronectin was effective in patients with persistent corneal epithelial defects and corneal ulcers.


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Administration, Topical , Blood Proteins/isolation & purification , Chromatography, Affinity , Corneal Diseases/drug therapy , Corneal Ulcer/drug therapy , Epithelium/drug effects , Fibronectins/administration & dosage , Visual Acuity , Wound Healing/drug effects
4.
Acta méd. colomb ; 11(4): 206-12, jul.-ago. 1986. tab, graf
Article in Spanish | LILACS | ID: lil-292765

ABSTRACT

Se estudio un grupo de 15 pacientes con patología traumática y/o séptica, en quienes se dosificaron los niveles iniciales de fibronectina (FN), encontrando cifras subnormales en todos los casos (X: 212 mcgr/ml). Posteriormente, cuando las condiciones clínicas empezaron a deteriorarse con alteraciones hemodinámicas importantes y falla respiratoria y/o neurológica, se administraron 10 unidades de criprecipitado del plasma, como suuplemento de su esquema terapéutico básico. Se obtuvo elevación de los niveles iniciales de FN hasta 306 mcgr/ml (p<0.02), a las dos horas de aplicación del crioprecipitado y normalización de éstos al séptimo día. Se correlacionaron los niveles bajos e FN con leucocitosis y aumento de cayados, cifras que al normalizarse coinciden con la elevación de FN y la mejoría del estado clínico. La mortalidad en este grupo fue de 21.4 por ciento. Nueve pacientes con patologías similares e idénticas medidas terapéuticas se tomaron como control sin administrarles crioprecipitados. La mortalidad fue del 78.6 por ciento. Reemplazar las perdidas de FN puede ser una nueva modalidad terapéutica, que amerita estudios aleatorios adecuados con el fin de establecer su verdadero valor en el manejo de los pacientes sépticos y traumatizados


Subject(s)
Humans , Burns/blood , Burns/drug therapy , Burns/therapy , Fibronectins/administration & dosage , Fibronectins/biosynthesis , Fibronectins/deficiency , Sepsis/blood , Sepsis/drug therapy , Sepsis/therapy , Multiple Trauma/drug therapy , Multiple Trauma/blood , Multiple Trauma/therapy
SELECTION OF CITATIONS
SEARCH DETAIL